Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis A vaccine (Butantan Foundation)
- Development stage
- Approved
- Lead developer
- Instituto Butantan
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The adsorbed inactivated hepatitis A vaccine, developed and produced by the Butantan Foundation, is an immunizing agent indicated for the active prevention of infection caused by the hepatitis A virus (HAV). The vaccine is composed of purified hepatitis A virus (typically the HM175 strain) grown in human diploid cells (MRC-5), which is subsequently inactivated with formaldehyde and adsorbed onto an aluminum hydroxide adjuvant to enhance its immunogenicity. Upon administration, the vaccine stimulates the immune system to produce specific neutralizing IgG antibodies against HAV, providing long-term protective immunity. It is a monovalent vaccine administered via intramuscular injection and is a key component of the Brazilian National Immunization Program (PNI), primarily targeted at children and high-risk populations to reduce the incidence of hepatitis A.
- Brand names
- Vacina adsorvida hepatite A (inativada)
- Other names
- adsorbed hepatitis A vaccineinactivated hepatitis A vaccine
Beyond the preview
Go deeper on hepatitis A vaccine (Butantan Foundation).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis A vaccine (Butantan Foundation).